A daily pill that works like Ozempic but without injections is now being assessed for NHS use in England and Wales. NICE is scheduled to meet in July 2026 to evaluate orforglipron, sold under the brand name Foundayo. Here is everything UK patients need to know before the reviews are complete.
A genuinely new type of weight loss medicine is making its way through the UK approval process. Orforglipron, branded as Foundayo and made by pharmaceutical company Eli Lilly, is an oral once-daily pill that activates the same hunger-regulating system as Ozempic and Mounjaro — but it is not a peptide and does not require an injection.
This development was announced on June 2026.
According to The Pharmaceutical Journal, the NICE committee — the independent body that decides which treatments the NHS in England and Wales should fund — is scheduled to meet in July 2026 to begin its assessment of orforglipron. The MHRA, which is the UK’s medicines regulator (the equivalent of the US FDA), is currently conducting its own separate review. Private availability in UK clinics is not expected before late 2026 at the earliest.
For anyone who has been following weight loss medicine, this is a significant moment. According to NICE, the orforglipron review will determine whether the NHS could eventually fund this treatment for eligible patients. That could open access to an entirely new format of weight loss medicine for millions of people in England and Wales.
What makes orforglipron different from Ozempic and Mounjaro?
Ozempic and Wegovy both contain semaglutide. Mounjaro contains tirzepatide. All three are peptides — that means they are made from chains of amino acids (the building blocks of protein). Because peptides break down in the stomach, they cannot currently be taken as a simple pill. That is why all existing GLP-1 weight loss medicines require an injection, typically once a week.
Orforglipron is different at a molecular level. According to The Pharmaceutical Journal, it is described as a non-peptide GLP-1 receptor agonist. In plain English: it switches on the same hunger and blood sugar signals in your body as semaglutide does, but it uses a completely different type of molecule. That molecule survives the digestive process, so it can be swallowed as a tablet and absorbed properly. This is a different medicine to the oral Wegovy pill, which is a peptide-based tablet form of semaglutide and received separate UK regulatory attention — orforglipron is made by Eli Lilly and uses an entirely different non-peptide molecule, even though both are taken as a daily tablet.
What do we know about how well it works?
Clinical trial data for orforglipron has been published, though the NICE committee has not yet issued its final assessment. According to The Pharmaceutical Journal, trial participants taking orforglipron achieved meaningful weight loss results, placing it broadly in a similar performance range to weekly injectable semaglutide medicines like Wegovy.
It is important to be clear that orforglipron is not tirzepatide and does not work on the dual GIP and GLP-1 pathways that Mounjaro uses. It is a single-receptor GLP-1 medicine, like Ozempic — just in pill form. Patients who respond well to Ozempic-type medicines may find orforglipron a compelling option once it becomes available, particularly those who find injections difficult or distressing.
The side effect profile in trials appears broadly similar to other GLP-1 medicines. Nausea, particularly in the early weeks, is the most commonly reported issue. According to The Pharmaceutical Journal, no significant unexpected safety signals have emerged from trial data published to date. The MHRA will conduct its own full safety assessment before any UK approval is granted.
For context on where orforglipron sits in the broader landscape of next-generation weight loss medicines, it is worth reading our guide to retatrutide, which is another emerging treatment currently under review. And if you are completely new to this area, our Start Here guide explains how all GLP-1 medicines work in plain English.
What This Means For UK Patients
Do not rush into anything yet. Orforglipron is not available in the UK as of June 2026, and no responsible private clinic can legally supply it here before MHRA approval. Anyone advertising Foundayo or orforglipron for sale in the UK right now should be treated with serious caution. The July 2026 NICE meeting is a scheduled committee date, not an approval announcement — the full NICE assessment process typically takes many months after an initial review. If you are currently on a waiting list for NHS weight loss treatment, orforglipron will not affect your position in the short term. However, if you find injections to be a genuine barrier to starting treatment, it is worth raising orforglipron with your GP now. Getting that conversation on record means you will be better placed when it does become available. Watch for the MHRA decision, which will come before any private prescribing in the UK can legally begin.
Frequently Asked Questions
What is orforglipron and what is Foundayo?
Orforglipron is the medicine’s scientific name. Foundayo is the brand name given to it by its manufacturer, Eli Lilly. According to The Pharmaceutical Journal, it is a once-daily oral tablet that activates GLP-1 receptors in the body to reduce appetite and regulate blood sugar — the same biological pathway targeted by Ozempic and Mounjaro.
Is orforglipron available in the UK yet?
No. As of June 2026, orforglipron is not approved or available in the UK. According to The Pharmaceutical Journal, the MHRA review is currently underway and private UK availability is not expected before late 2026 at the earliest.
Will the NHS fund orforglipron?
That decision has not been made yet. According to NICE, a committee is scheduled to meet in July 2026 to begin its assessment. A full NICE appraisal typically takes several months before a funding recommendation is issued for England and Wales.
How is orforglipron different from semaglutide or tirzepatide?
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are peptide molecules that must be injected because they cannot survive digestion. According to The Pharmaceutical Journal, orforglipron is a non-peptide molecule that works on the same GLP-1 receptor but is chemically stable enough to be taken as a daily tablet.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.
Get the UK peptide medicine briefing in your inbox.
Free weekly. No spam. Unsubscribe any time.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment. Information correct at time of publication. The Peptide Brief updates articles when guidance changes.
